Loading company…
Neuro Dawn develops drugs for central nervous system conditions.
Founded in 2020 and based in Nanjing, China, Neuro Dawn researches drugs for cognitive impairment, affective disorders, neuropathic pain, and cerebrovascular disease. Its pipeline includes projects for Alzheimer's disease, stroke, and other conditions. The company closed Series C funding in November 2024 to support pipeline development and global growth.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in